Solar urticaria is a rare but debilitating disease that can severely impact the quality of life, restricting outdoor activities.Treatment, based on sun protection and anti-histaminic drugs, is efficacious in 2 patients out of 3. In refractory patients, photodesensitization or immunosuppressive treatments such as cyclosporin A can be proposed. As in idiopathic urticaria, intravenous immunoglobulins (IVIG)have been shown, in a retrospective study of 7 patients, to dramatically improve 71% of patients. In an open-label prospective multicenter study, we aim to demonstrate the efficacy of a single IVIG administration (2g/kg) in 10 patients affected with severe and refractory solar urticaria.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Regional University Hospital
Besançon, France
University Hospital
Caen, France
University Hospital
Grenoble, France
Regional University Hospital
Lille, France
University hospital
Limoges, France
Regional University Hospital
Montpellier, France
University Hospital
Nancy, France
University Hospital
Nîmes, France
Saint louis Hospital
Paris, France
University Hospital
Reims, France
...and 2 more locations
Percentage of patients obtaining 3 months after treatment a 10 fold increase of pretherapeutic minimal urticarial dose
Time frame: 3 months
Percentage of patients obtaining 1 month after treatment a 10 fold increase of pretherapeutic minimal urticarial dose
Time frame: 1 month
Percentage of patients obtaining 1 month after treatment an improvement of quality of life
Time frame: 1 month
Percentage of patients obtaining after 1 month of treatment a complete clinical response
Time frame: 1 month
Percentage of patients obtaining 1 month after treatment a 50% and a 75% improvement of disease severity
Time frame: 1 month
Percentage of patients obtaining 6 months after treatment a 10 fold increase of pretherapeutic minimal urticarial dose
Time frame: 6 months
Percentage of patients obtaining 12 months after treatment a 10 fold increase of pretherapeutic minimal urticarial dose
Time frame: 12 months
Percentage of patients obtaining 3 months after treatment an improvement of quality of life
Time frame: 3 months
Percentage of patients obtaining 6 months after treatment an improvement of quality of life
Time frame: 6 months
Percentage of patients obtaining 12 months after treatment an improvement of quality of life
Time frame: 12 months
Percentage of patients obtaining after 3 months of treatment a complete clinical response
Time frame: 3 months
Percentage of patients obtaining after 6 months of treatment a complete clinical response
Time frame: 6 months
Percentage of patients obtaining after 12 months of treatment a complete clinical response
Time frame: 12 months
Percentage of patients obtaining 3 months after treatment a 50% and a 75% improvement of disease severity
Time frame: 3 months
Percentage of patients obtaining 6 months after treatment a 50% and a 75% improvement of disease severity
Time frame: 6 months
Percentage of patients obtaining 12 months after treatment a 50% and a 75% improvement of disease severity
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.